Finoriq research workspace
Adicet Bio, Inc. (ACET) SEC Filings & Filing Highlights
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma. Review ACET SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
- Company
- Adicet Bio, Inc. (ACET)
- Ticker
- ACET
- Market Cap
- $74.7M
- Latest Price
- $7.99
- Industry
- Biotech & Pharma
Adicet Bio, Inc. (ACET) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Adicet Bio, Inc. (ACET).
| Event | Form | Date |
|---|---|---|
| Proposal 1 – Election of Class II Director NomineesOn June 17, 2026, Adicet Bio, Inc., a Delaware corporation (the “Company”), held its 2026 Annual Meeting of Stockholders (the “Annual Meeti... | 8-K5.07 | 2026-06-18 |
| Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business UpdatesAdicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates | 8-K2.02 | 2026-05-13 |
| The Company issued the Pre-Funded Warrant without registration in reliance on the exemption fro...On April 27, 2026, Adicet Bio, Inc. (the Company) entered into an exchange agreement with RA Capital Management, L.P. and RA Capital Health... | 8-K3.02 | 2026-04-28 |
| Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Co...Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress | 8-K2.02 | 2026-03-12 |
| Adicet Bio Provides Corporate Update and Highlights Expected 2026 MilestonesAdicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones | 8-K8.01 | 2026-01-07 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.